IDiyas

For the Inventor, By the Inventor

King of Prussia, PA, United States of America

Colin Andrew Leach

USPTO Granted Patents = 20 

Average Co-Inventor Count = 3.5

ph-index = 5

Forward Citations = 97(Granted Patents)


Location History:

  • Hertfordshire, GB (1995 - 1999)
  • Roydon, GB (2000)
  • Sawbridgeworth, GB (2003)
  • Stevenage, GB (2002 - 2006)
  • Harlow, GB (2003 - 2010)
  • King of Prussia, PA (US) (2007 - 2010)
  • Essex, GB (2014 - 2016)

Company Filing History:

goldMedal16 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal3 out of 1,168 
 
Glaxo Group Limited
 patents
bronzeMedal1 out of 6 
 
Smithkline Beecham Intercredit B.v.
 patents

Years Active: 1995-2016

Loading Chart...
20 patents (USPTO):Explore Patents
1. 9266841 - Compounds (2016-02-23),
2. 8871775 - Compounds (2014-10-28),
3. 7705005 - Bicyclic heteroaromatic compounds (2010-04-27),
4. 7652019 - 5,6-trimethylenepyrimidin-4-one compounds (2010-01-26),
5. 7638520 - Pyrimidine compounds (2009-12-29),
6. 7470694 - 5,6-trimethylenepyrimidin-4-one compounds (2008-12-30),
7. 7462620 - Pyrimidinone derivatives and their use in the treatment of atherosclerosis (2008-12-09),
8. 7235566 - Pyridinone derivatives for treatment of atherosclerosis (2007-06-26),
9. 7169924 - Pyrimidinone derivatives and their use in the treatment of atherosclerosis (2007-01-30),
10. 7153861 - 5,6 -Trimethylenepyrimidin-4-one compounds (2006-12-26),
11. 7115616 - Pyrimidinone compounds (2006-10-03),
12. 6953803 - Pyrimidine compounds (2005-10-11),
13. 6762034 - Resorufin derivatives as substrates for CYP3A4 (2004-07-13),
14. 6649619 - Compounds (2003-11-18),
15. 6559155 - Pyrimidinone derivatives for the treatment of atherosclerosis (2003-05-06),

Title: The Innovative Journey of Colin Andrew Leach

Introduction: Colin Andrew Leach, located in King of Prussia, Pennsylvania, is a distinguished inventor known for his contributions to the field of medicinal chemistry. With a remarkable portfolio of 20 patents, Leach has made significant strides in developing new compounds that have the potential to improve health outcomes, particularly in the treatment of atherosclerosis.

Latest Patents: Among his latest innovations, Leach has focused on Pyrimidone compounds, which are proven inhibitors of the enzyme Lp-PLA. These compounds hold promise in the treatment of atherosclerosis, representing a significant advancement in therapeutic approaches to this common cardiovascular condition.

Career Highlights: Throughout his career, Colin Andrew Leach has held key positions in renowned companies such as SmithKline Beecham Corporation and Glaxo Group Limited. His work at these organizations has been pivotal in advancing pharmaceutical research and development.

Collaborations: Leach has collaborated with notable professionals in the industry, including Stephen Allan Smith and Robert John Ife. Their collective expertise has contributed to the success of various research initiatives and innovative projects.

Conclusion: Colin Andrew Leach's dedication to innovation in pharmaceutical sciences places him at the forefront of modern medicine. His extensive patent portfolio reflects his expertise and commitment to creating solutions that address critical health challenges. As he continues to push the boundaries of research, the impact of his work will be felt in the healthcare industry for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…